142 related articles for article (PubMed ID: 32313236)
21. Radiomics Study of Thyroid Ultrasound for Predicting
Kwon MR; Shin JH; Park H; Cho H; Hahn SY; Park KW
AJNR Am J Neuroradiol; 2020 Apr; 41(4):700-705. PubMed ID: 32273326
[TBL] [Abstract][Full Text] [Related]
22. BRAF-V600 mutational status affects recurrence patterns of melanoma brain metastasis.
Maxwell R; Garzon-Muvdi T; Lipson EJ; Sharfman WH; Bettegowda C; Redmond KJ; Kleinberg LR; Ye X; Lim M
Int J Cancer; 2017 Jun; 140(12):2716-2727. PubMed ID: 27342756
[TBL] [Abstract][Full Text] [Related]
23. Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment.
Ly D; Bagshaw HP; Anker CJ; Tward JD; Grossmann KF; Jensen RL; Shrieve DC
J Neurosurg; 2015 Aug; 123(2):395-401. PubMed ID: 25768829
[TBL] [Abstract][Full Text] [Related]
24. Melanoma brain metastases: correlation of imaging features with genomic markers and patient survival.
Bordia R; Zhong H; Lee J; Weiss S; Han SW; Osman I; Jain R
J Neurooncol; 2017 Jan; 131(2):341-348. PubMed ID: 27822597
[TBL] [Abstract][Full Text] [Related]
25. Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.
Casadevall D; Vidal J; Gallardo F; Zuccarino F; Arumí-Uría M; Dalmases A; Bellosillo B; Montagut C
J Med Case Rep; 2016 Jun; 10(1):158. PubMed ID: 27255157
[TBL] [Abstract][Full Text] [Related]
26. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
[TBL] [Abstract][Full Text] [Related]
27. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms.
Behling F; Barrantes-Freer A; Skardelly M; Nieser M; Christians A; Stockhammer F; Rohde V; Tatagiba M; Hartmann C; Stadelmann C; Schittenhelm J
Diagn Pathol; 2016 Jun; 11(1):55. PubMed ID: 27350555
[TBL] [Abstract][Full Text] [Related]
28. Melanoma brain metastases harboring BRAF
Fang P; Boehling NS; Koay EJ; Bucheit AD; Jakob JA; Settle SH; Brown PD; Davies MA; Sulman EP
J Neurooncol; 2018 Mar; 137(1):67-75. PubMed ID: 29198052
[TBL] [Abstract][Full Text] [Related]
29. Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases.
Wolf A; Zia S; Verma R; Pavlick A; Wilson M; Golfinos JG; Silverman JS; Kondziolka D
J Neurooncol; 2016 May; 127(3):607-15. PubMed ID: 26852222
[TBL] [Abstract][Full Text] [Related]
30. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.
Robinson SD; O'Shaughnessy JA; Cowey CL; Konduri K
Lung Cancer; 2014 Aug; 85(2):326-30. PubMed ID: 24888229
[TBL] [Abstract][Full Text] [Related]
31. Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.
Kotecha R; Miller JA; Venur VA; Mohammadi AM; Chao ST; Suh JH; Barnett GH; Murphy ES; Funchain P; Yu JS; Vogelbaum MA; Angelov L; Ahluwalia MS
J Neurosurg; 2018 Jul; 129(1):50-59. PubMed ID: 28799876
[TBL] [Abstract][Full Text] [Related]
32. Multimodal integration of image, epigenetic and clinical data to predict BRAF mutation status in melanoma.
Schneider L; Wies C; Krieghoff-Henning EI; Bucher TC; Utikal JS; Schadendorf D; Brinker TJ
Eur J Cancer; 2023 Apr; 183():131-138. PubMed ID: 36854237
[TBL] [Abstract][Full Text] [Related]
33. Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases.
Gummadi T; Zhang BY; Valpione S; Kim C; Kottschade LA; Mittapalli RK; Chiarion-Sileni V; Pigozzo J; Elmquist WF; Dudek AZ
Melanoma Res; 2015 Feb; 25(1):75-9. PubMed ID: 25426645
[TBL] [Abstract][Full Text] [Related]
34. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.
Long GV; Trefzer U; Davies MA; Kefford RF; Ascierto PA; Chapman PB; Puzanov I; Hauschild A; Robert C; Algazi A; Mortier L; Tawbi H; Wilhelm T; Zimmer L; Switzky J; Swann S; Martin AM; Guckert M; Goodman V; Streit M; Kirkwood JM; Schadendorf D
Lancet Oncol; 2012 Nov; 13(11):1087-95. PubMed ID: 23051966
[TBL] [Abstract][Full Text] [Related]
35. Innate immune cell infiltration in melanoma metastases affects survival and is associated with BRAFV600E mutation status.
Dabrosin N; Sloth Juul K; Bæhr Georgsen J; Andrup S; Schmidt H; Steiniche T; Heide Øllegaard T; Bønnelykke Behrndtz L
Melanoma Res; 2019 Feb; 29(1):30-37. PubMed ID: 30299387
[TBL] [Abstract][Full Text] [Related]
36. On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases.
Gaudy-Marqueste C; Carron R; Delsanti C; Loundou A; Monestier S; Archier E; Richard MA; Regis J; Grob JJ
Ann Oncol; 2014 Oct; 25(10):2086-2091. PubMed ID: 25057167
[TBL] [Abstract][Full Text] [Related]
37. Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile.
Larsen AC
Acta Ophthalmol; 2016 May; 94 Thesis 1():1-27. PubMed ID: 27192168
[TBL] [Abstract][Full Text] [Related]
38. An open-label, multicentre safety study of vemurafenib in patients with BRAF
Larkin J; Brown MP; Arance AM; Hauschild A; Queirolo P; Vecchio MD; Ascierto PA; Krajsová I; Schachter J; Neyns B; Garbe C; Sileni VC; Mandalà M; Gogas H; Espinosa E; Hospers G; Lorigan P; Nyakas M; Guminski A; Liszkay G; Rutkowski P; Miller W; Donica M; Makrutzki M; Blank C
Eur J Cancer; 2019 Jan; 107():175-185. PubMed ID: 30580112
[TBL] [Abstract][Full Text] [Related]
39. Radiomics of Brain MRI: Utility in Prediction of Metastatic Tumor Type.
Kniep HC; Madesta F; Schneider T; Hanning U; Schönfeld MH; Schön G; Fiehler J; Gauer T; Werner R; Gellissen S
Radiology; 2019 Feb; 290(2):479-487. PubMed ID: 30526358
[TBL] [Abstract][Full Text] [Related]
40. Distinct genetic profiles of extracranial and intracranial acral melanoma metastases.
Sharma G; Lian CG; Lin WM; Amin-Mansour A; Jané-Valbuena J; Garraway L; Bao W; Yoon CH; Ibrahim N
J Cutan Pathol; 2016 Oct; 43(10):884-91. PubMed ID: 27251777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
